Take advantage of nanomaterials to properly regulate the inflammatory response.

In particular, colloidal nanoparticles are exploited to improve the delivery of a peptide (VIVIT) that inhibits calcineurin/NFAT pathway (Patent WO2014013473-A1). The developed drug delivery systems are investigated for the treatment of several pathological conditions (e.g., transplantation rejection, chronic lymphocytic leukaemia) by targeting specific immune cells.